| Metabolism of non-enzymatically derived oxysterols: clues from sterol metabolic disorders WJ Griffiths, E Yutuc, J Abdel-Khalik, PJ Crick, T Hearn, A Dickson, ... Free Radical Biology and Medicine 144, 124-133, 2019 | 50 | 2019 |
| Identification of unusual oxysterols and bile acids with 7-oxo or 3β, 5α, 6β-trihydroxy functions in human plasma by charge-tagging mass spectrometry with multistage … WJ Griffiths, I Gilmore, E Yutuc, J Abdel-Khalik, PJ Crick, T Hearn, ... Journal of lipid research 59 (6), 1058-1070, 2018 | 25 | 2018 |
| Charge-tagging liquid chromatography–mass spectrometry methodology targeting oxysterol diastereoisomers WJ Griffiths, T Hearn, PJ Crick, J Abdel-Khalik, A Dickson, E Yutuc, ... Chemistry and physics of lipids 207, 69-80, 2017 | 21 | 2017 |
| Deep mining of oxysterols and cholestenoic acids in human plasma and cerebrospinal fluid: Quantification using isotope dilution mass spectrometry E Yutuc, AL Dickson, M Pacciarini, L Griffiths, PRS Baker, L Connell, ... Analytica Chimica Acta 1154, 338259, 2021 | 19 | 2021 |
| Bile acid biosynthesis in Smith-Lemli-Opitz syndrome bypassing cholesterol: potential importance of pathway intermediates J Abdel-Khalik, T Hearn, AL Dickson, PJ Crick, E Yutuc, K Austin-Muttitt, ... The Journal of steroid biochemistry and molecular biology 206, 105794, 2021 | 18 | 2021 |
| The novel anti-cancer fluoropyrimidine NUC-3373 is a potent inhibitor of thymidylate synthase and an effective DNA-damaging agent J Bré, AL Dickson, OJ Read, Y Zhang, FG McKissock, P Mullen, P Tang, ... Cancer Chemotherapy and Pharmacology 91 (5), 401-412, 2023 | 11 | 2023 |
| Lipidomics basics WJ Griffiths, E Yutuc, D Davies, A Dickson, R Angelini, D El Assad, ... | 8 | 2020 |
| Identification of unusual oxysterols biosynthesised in human pregnancy by charge-tagging and liquid chromatography-mass spectrometry AL Dickson, E Yutuc, CA Thornton, Y Wang, WJ Griffiths Frontiers in Endocrinology 13, 1031013, 2022 | 6 | 2022 |
| Snapshots of the reaction coordinate of a thermophilic 2′-deoxyribonucleoside/ribonucleoside transferase P Tang, CJ Harding, AL Dickson, RG da Silva, DJ Harrison, CM Czekster ACS catalysis 14 (5), 3090-3102, 2024 | 5 | 2024 |
| Catalytic cycle of the bifunctional enzyme phosphoribosyl-ATP pyrophosphohydrolase/phosphoribosyl-AMP cyclohydrolase G Fisher, E Pečaver, BJ Read, SK Leese, E Laing, AL Dickson, ... ACS catalysis 13 (11), 7669-7679, 2023 | 5 | 2023 |
| Human 2′-Deoxynucleoside 5′-Phosphate N-Hydrolase 1: Mechanism of 2′-Deoxyuridine 5′-Monophosphate Hydrolysis S Devi, AE Carberry, GM Zickuhr, AL Dickson, DJ Harrison, RG da Silva Biochemistry 62 (17), 2658-2668, 2023 | 4 | 2023 |
| HSD3B1 is an oxysterol 3β-hydroxysteroid dehydrogenase in human placenta A Dickson, E Yutuc, CA Thornton, JE Dunford, U Oppermann, Y Wang, ... Open biology 13 (5), 220313, 2023 | 4 | 2023 |
| 666P Final results of phase I/II study of NUC-7738 as monotherapy and in combination with pembrolizumab: Anti-tumor immune response in PD-1 inhibitor-resistant patients S Blagden, M Elshani, SN Symeonides, A Skolariki, NR Haris, ZY Boh, ... Annals of Oncology 35, S523-S524, 2024 | | 2024 |
| DESI-MSI-guided exploration of metabolic-phenotypic relationships reveals a correlation between PI 38: 3 and proliferating cells in clear cell renal cell carcinoma via single … GM Zickuhr, IH Um, A Laird, DJ Harrison, AL Dickson Analytical and Bioanalytical Chemistry, 1-14, 2024 | | 2024 |
| Defining the mode of action of cisplatin combined with a phosphoramidate modification of gemcitabine D Patel, AL Dickson, GM Zickuhr, IH Um, OJ Read, CM Czekster, P Mullen, ... | | 2024 |
| Exposing the heterogeneity of the lipidome in the TME of cutaneous melanoma following treatment with NUC-7738 in combination with anti-PD-1 therapy AL Dickson, GM Zickuhr, IH Um, Y Zhang, R Plummer, SP Blagden, ... Cancer Research 84 (6_Supplement), 6222-6222, 2024 | | 2024 |
| RNA regulatory disruption by 3’-dATP: A novel approach to inhibit ribosome biogenesis in cancer M Elshani, Y Zhang, IH Um, R Plummer, SP Blagden, SN Symeonides, ... Cancer Research 84 (6_Supplement), 5650-5650, 2024 | | 2024 |
| Abstract C032: NUC-7738 in combination with pembrolizumab in patients with metastatic melanoma: Phase 2 results from the NuTide: 701 study SP Blagden, SN Symeonides, A Skolariki, NM Haris, Z Boh, IH Um, ... Molecular Cancer Therapeutics 22 (12_Supplement), C032-C032, 2023 | | 2023 |
| NUC-7738 promotes alternative polyadenylation site usage and reduces glutaminase GAC isoform M Elshani, Y Zhang, T Hawkins, M Kudsy, IH Um, G Zickuhr, AL Dickson, ... Cancer Research 83 (7_Supplement), 277-277, 2023 | | 2023 |
| NUC-7738 causes reduction of soluble and exosome-associated PD-L1 in melanoma cell lines and patients M Elshani, Y Zhang, B Kaghazchi, AL Dickson, SP Blagden, ... Cancer Research 83 (7_Supplement), 5962-5962, 2023 | | 2023 |
